Private equity in ABA: who is actually across the table

Why private equity came to ABA

Three conditions had to be true at once, and by around 2018 they were.

The revenue became reliable. Beginning with early state mandates and completing across all fifty states, autism services acquired something most healthcare niches lack: a legal requirement that somebody pay for them. Commercial insurance mandates and Medicaid coverage together turned a discretionary purchase into a funded benefit.

The revenue became large. ABA is not a service delivered in fifteen-minute increments. Intensive programs run to many hours per week per child, sustained over years. That produces revenue per client that few outpatient services can match.

The market was fragmented. Thousands of independent clinics, most owned by clinicians, most subscale, most without sophisticated billing or contracting. From an investor's point of view this is not a problem to solve, it is the opportunity itself: buy many small ones, combine them, and sell the combined entity at a higher multiple than any of the parts commanded individually.

That last point is worth understanding precisely, because it is the entire engine. A single clinic doing two million dollars of revenue trades at a modest multiple. A platform doing eighty million trades at a considerably higher one, for the same underlying work. The value is created by aggregation itself. This is called multiple arbitrage, and it is why an acquirer can pay you more than your practice is worth to you and still profit.

What the model actually is

A private equity fund buys a platform company, usually with a substantial portion of the purchase price funded by debt that is placed on the acquired company rather than on the fund. It then buys smaller practices, folds them in, and works to increase earnings. After some years, typically three to seven, it sells the combined business or recapitalises it, and returns the proceeds to its investors.

Nothing in that description is sinister. It is a legitimate financial structure that has built real businesses. But two features of it matter enormously to a clinic owner, and they are rarely explained.

The debt sits on the company, not the fund. If the combined business cannot service the debt, the business fails. The fund's downside is limited to the equity it put in. Yours, if you rolled equity or stayed on, is not so cleanly bounded.

The clock is not yours. A fund has a defined life and its investors expect a return within it. Decisions that would be irrational for a permanent owner, closing a marginally profitable clinic, stripping a service line that does not scale, cutting clinical overhead that does not show up in this year's earnings, are entirely rational for an owner who must sell within four years. This is not a moral failing. It is the arithmetic of the structure, and it will continue to be true regardless of who the individuals are.

The CARD collapse, read as an owner

The Center for Autism and Related Disorders is the case everyone in ABA has heard of and few have examined closely. It is worth the detail, because the useful lessons are operational rather than moral.

CARD was founded in 1990 and grew over three decades into one of the largest ABA providers in the country, with roughly 250 sites at its peak. In May 2018 Blackstone acquired it in a leveraged buyout reported at approximately six hundred million dollars, the largest transaction the sector had seen. The stated plan was aggressive expansion toward several hundred clinics.

What happened instead: by 2022 the company had begun closing sites and exiting entire state markets. On June 11, 2023 it filed for Chapter 11 protection in the Southern District of Texas. Court filings disclosed trailing revenue of roughly $160 million against a net loss of about $82 million. On July 27, 2023 the bankruptcy court approved a sale of the business for a total transaction value of $48.5 million, with a consortium led by the original founder acquiring the core brand and ten state markets, and other assets going to other buyers, in one case for a nominal sum.

Read those two numbers next to each other. Acquired for roughly six hundred million dollars in 2018. Sold out of bankruptcy for $48.5 million in 2023.

What actually went wrong

The temptation is to conclude that private equity destroyed the company through greed. The more useful and more accurate reading is that the structure was fragile and the sector turned out not to behave the way the model assumed.

The proximate cause reported in the coverage was the debt: the company could not service the borrowing taken on to fund aggressive growth. But the deeper problem is that ABA does not scale the way the thesis required. It is a labour business. The margin depends on recruiting, credentialing, and retaining behavior analysts and technicians in a market where they are chronically scarce, and on payer reimbursement rates that the operator does not control and cannot raise. When rates stayed flat and labour costs rose, the margin compressed, and a business carrying heavy debt has no room to absorb margin compression.

That is the lesson worth carrying, and it applies whether or not you ever meet a private equity firm: in ABA, clinical staffing is not an overhead line, it is the product. An owner who cuts supervision to protect earnings is not trimming cost, they are consuming the asset. And a buyer who does not understand that will do it anyway.

What this means if you are the seller

None of the above is an argument against selling to private equity. Plenty of owners have done so and done well. It is an argument for understanding what you are dealing with. Concretely:

• They are buying a financial asset, and they will diligence it like one. Your clinical excellence is a precondition, not a selling point. What gets examined is revenue quality, payer mix, authorization stability, staff retention, and whether your entity was ever legally entitled to bill for the work it billed for.
• The offer is often structured, not paid. A headline number typically comprises cash at closing, an earnout tied to future performance, and rolled equity in the acquiring platform. The last of those is only worth what the platform is eventually worth. If you are rolling equity, you are not exiting. You are reinvesting, in a business someone else now controls, that may be carrying substantial debt.
• Your leverage is highest before diligence, and it never recovers. Every problem found after the letter of intent is a reason to reprice. Every problem fixed before it is invisible.
• Continuity is what they are actually buying. If your supervising analysts leave during or after the transaction, the revenue they support leaves with them, and the buyer knows this. It is why retention is diligenced and why it is priced.

Why your structure determines your buyer

This is where the topic connects to everything else in this knowledge base, and it is the part owners most often discover too late.

Whether an outside investor can hold equity in your practice at all is a question of state law. In most of the states we cover, behavior analysis is not reached by the professional-entity and corporate-practice rules that restrict ownership of medical practices, which means a standard company owned by a non-licensee can operate an ABA practice and an investor can simply buy it. In a minority of states the answer is different, and in Illinois it is a hard deadline: non-licensee ownership of ABA practices must be divested by January 15, 2027 (225 ILCS 6/150).

Where direct ownership is restricted, capital comes in through a management services organisation instead, which owns no equity in the clinical entity and is paid a management fee. That structure is legitimate and common, and it is also the structure that regulators are now examining most closely.

The practical consequence for a seller is blunt: if your structure does not permit the buyer to acquire what they think they are acquiring, the deal changes shape or dies. Establish what you actually have before anyone else does. Start with the entity decision and ownership and MSOs.

The backlash is now law

For most of the last decade the regulatory environment for healthcare roll-ups was, in the words of one industry assessment, favourable. That is changing, and quickly.

At the federal level, the Federal Trade Commission and the Department of Health and Human Services have opened an inquiry into private equity and corporate takeovers of healthcare entities, examining consolidation and its effects on patients, workers, and cost.

At the state level the movement is more consequential, because the states are where ownership is actually regulated. Oregon enacted the most restrictive management-company law in the country, prohibiting an MSO and the people affiliated with it from owning or controlling a majority of the professional entity it manages, sharply limiting the equity transfer restriction agreements that made friendly-owner structures enforceable, voiding most non-competition agreements with clinicians, and making violations an unlawful trade practice with attorney-general enforcement and private damages (Oregon SB 951 (2025), amending ORS 58.375 and 58.376). Legislators in a number of other states have proposed or passed measures increasing scrutiny of healthcare transactions and corporate control.

An important caveat, and one that cuts in ABA's favour: the Oregon law reaches physicians, physician associates, nurse practitioners, and naturopathic physicians, and is understood to except certain behavioral health entities. A practice delivering only behavior analysis through licensed behavior analysts appears to fall outside its core prohibitions. But the direction of travel is unmistakable, and it would be complacent to assume behavior analysis stays outside the frame indefinitely.

How that shrinks your buyer pool

Here is the consequence that owners rarely connect, and it is the one with a number attached to it.

Laws restricting how investors may own and control practices do not merely inconvenience the investors. They reduce the number of buyers who can lawfully structure a purchase of your business. A smaller pool of buyers means less competitive tension in your process. Less competitive tension means a lower price. Commentators analysing the Oregon law noted exactly this: that its breadth may deter investment, narrow the pool of potential buyers, and consequently affect market valuations.

So the regulatory wave is not a distant policy matter. It runs directly through your exit multiple. And it argues for a specific posture: build a structure that a compliant buyer can acquire cleanly, because the buyers who cannot structure around a problem are precisely the buyers who will pay you the most.

Private equity is not automatically the villain

It would be easy to read this guide as an argument against selling to a fund. It is not.

Institutional capital brought real things to ABA: it professionalised billing and contracting in an industry that was often bad at both, funded expansion into areas with genuine waiting lists, and gave founders a route to liquidity that did not exist before. Many owners have sold to private-equity-backed platforms, been paid properly, and left staff in a stronger organisation than the one they built alone. That happens, and it happens often.

The point is narrower and it is this. The interests of a fund and the interests of a founder are aligned on some things, growth, professionalisation, price, and are not aligned on others, time horizon, leverage tolerance, and what happens to the clinical model after you are gone. An owner who understands where the alignment ends negotiates for it. An owner who assumes the buyer shares their values negotiates for nothing.

Frequently asked questions